Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

By C. D. Williams, Joel Z Stengel, Michael Asike, D. Torres, J. Shaw, M. Contreras, Cristy L Landt, S. Harrison. Gastroenterology, 2011

2,130 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/ef15a6fe8ed1e34813a8402640bda02126f28f9b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. R. Loomba

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. K. Cusi
5. A. Sanyal
6. J. Clark
7. A. Baranova
8. Y. Kawano

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. R. Loomba
6. J. Clark
7. Y. Kawano
8. D. Cohen

Citations in the corpus

• The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review (2023, methodology): “To reduce overestimation associated with a referral for liver biopsy, we only included studies with subjects who were not specifically referred for liver biopsy based on a clinical indication such as elevated liver enzymes.[26,27] Subsequently, the NASH prevalence in the general population was estim”
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, background): “4 % of patients had NASH and 12% had advanced fibrosis (F3-4), which is higher than in a general population [25].”
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “For this analysis, it was estimated that 20-25% of those with NAFLD currently have NASH and that about 20% of those with NASH have ≥ F3 fibrosis (21-25).”
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, methodology): “2%.(14) In the Dallas Heart Study, when assessed by MR spectroscopy the prevalence of NAFLD in the general population was 31%.”
• Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. (2012, background): “The rate of biopsy-proven NAFLD among diabetics may reach 74% [25,26], and NAFLD is commonly associated with insulin resistance and hyperinsulinemia even in the non-obese [27].”
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (2011, background): “study from Dallas County, Texas identified NAFLD in 31% of a multi-ethnic, population-based sample.(16) Other studies have used elevations in the liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as non-invasive indicators of”